Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions DOI Open Access
M H Miran Beygi, Salma Ahi, Samaneh Zolghadri

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(14), P. 2220 - 2220

Published: July 11, 2024

Non-alcoholic fatty liver disease (NAFLD) is a common long-lasting that affects millions of people around the world. It best identified with hepatic fat build-up ultimately leads to inflammation and damage. The classification nomenclature NAFLD have long been controversial topic, until 2020 when group international experts recommended substituting MAFLD (metabolic dysfunction-associated FLD). was then terminologically complemented in 2023 by altering it MASLD, i.e., metabolic steatotic (MASLD). Both MASLD terminologies comprise element disorder, as they offer diagnostic benchmarks are embedded risk factors underlie disease. (as multisystemic disease) provides comprehensive definition includes larger population patients who at morbidity mortality, well adverse cardiovascular diabetes outcomes. highlights risks lean or normal weight individuals, factor has not accentuated discussed previous guidelines. Novel antihyperglycemic agents, anti-hyperlipidemic drugs, lifestyle modifications, nutritional interventions, exercise therapies extensively studied MASLD. Nutrition plays vital role managing both conditions, where centralizing on diet rich whole vegetables, fruits, foods, healthy fats, proteins, specific nutrients (e.g., omega-3 acids fibers) can improve insulin resistance reduce inflammation. Thus, essential understand nutrition these conditions work develop an individualized plan for optimal health. This review discusses prevention strategies NAFLD/MAFLD/MASLD management, particular attention correction.

Language: Английский

Natural history of metabolic dysfunction-associated steatotic liver disease DOI
Vasileios Lekakis, George Papatheodoridis

European Journal of Internal Medicine, Journal Year: 2023, Volume and Issue: 122, P. 3 - 10

Published: Nov. 7, 2023

Language: Английский

Citations

58
Epidemiology of Metabolic Dysfunction Associated Steatotic Liver Disease DOI Creative Commons
Zobair M. Younossi,

Markos Kalligeros,

Linda Henry

et al.

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 19, 2024

As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does prevalence metabolic dysfunction associated steatotic liver disease (MASLD). Currently, 38% all adults 7-14% children adolescents have MASLD. By 2040, MASLD rate for is projected over 55%. Although many with will not develop progressive disease, given vast number patients MASLD, it has now become top indication transplant in United States those hepatocellular carcinoma (HCC) women. However, most common cause mortality among remains death cardiovascular diseases. In addition outcomes (cirrhosis HCC), increased risk developing de-novo T2D, chronic kidney sarcopenia extrahepatic cancers. Furthermore, decreased health related quality life, work productivity, fatigue healthcare resource utilization substantial economic burden. Similar other lifestyle interventions heathy diet physical activity remain cornerstone managing these patients. a T2D drugs are available treat co-morbid Resmetirom only MASH-targeted medication that was recently approved by Federal Drug Administration use stage 2-3 fibrosis. The following review provides an overview epidemiology, its factors demonstrates without further global initiatives, may increase.

Language: Английский

Citations

50
MAFLD predicts cardiovascular disease risk better than MASLD DOI
Ziyan Pan, Gamal Shiha, Gamal Esmat

et al.

Liver International, Journal Year: 2024, Volume and Issue: 44(7), P. 1567 - 1574

Published: April 20, 2024

Abstract Background and Aim Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic fatty (MAFLD). We compared abilities MAFLD MASLD to predict risk atherosclerotic cardiovascular (ASCVD). Methods Six thousand ninety six participants from 2017 2020 National Health Nutrition Examination Survey cohort who received a thorough medical health check‐up were chosen study. The associations between status coronary surrogates, such 10‐year ASCVD self‐reported events, analysed. Results identified in 2911 (47.7%) 2758 (45.2%) patients, respectively. (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78–2.57, p < .001) was more strongly independently associated with high than (OR: 1.82, CI, 1.52–2.18, comparison absence each condition. However, MAFLD, alone not increased risk. Multiple logistic regression revealed that significantly 2.82; CI: 1.13–7.01; .03) alone. Conclusions Although both different risks, predicted better MASLD. higher predictive ability attributed dysfunction rather moderate alcohol use.

Language: Английский

Citations

36
Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies DOI Creative Commons
Mohammad Habibullah,

Khaleed Jemmieh,

Amr Ouda

et al.

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: Jan. 23, 2024

Background Metabolic associated fatty liver disease (MAFLD) is a novel terminology introduced in 2020 to provide more accurate description of with metabolic dysfunction. It replaces the outdated term nonalcoholic (NAFLD) and aims improve diagnostic criteria tailored treatment strategies for disease. NAFLD, most prevalent western industrialized nations, has been steadily increasing prevalence serious complications such as cirrhosis hepatocellular carcinoma. also linked insulin resistance syndrome cardiovascular diseases. However, current studies on NAFLD have limitations meeting necessary histological endpoints. Objective This literature review consolidate recent knowledge discoveries concerning MAFLD, integrating diverse aspects Specifically, it focuses analyzing differentiating from alcoholic (AFLD), exploring epidemiology, clinical manifestations, pathogenesis, management approaches MAFLD. The explores associations between MAFLD other conditions. discusses heightened mortality risk its link chronic kidney (CKD), showing that exhibits enhanced accuracy identifying patients CKD compared NAFLD. association incident/prevalent supported by cohort meta-analyses. Conclusion highlights importance distinct provides insights into criteria, CKD, Further research needed develop tools advanced fibrosis explore underlying mechanisms linking serves valuable resource researchers healthcare professionals seeking comprehensive understanding

Language: Английский

Citations

31
Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions DOI Open Access
M H Miran Beygi, Salma Ahi, Samaneh Zolghadri

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(14), P. 2220 - 2220

Published: July 11, 2024

Non-alcoholic fatty liver disease (NAFLD) is a common long-lasting that affects millions of people around the world. It best identified with hepatic fat build-up ultimately leads to inflammation and damage. The classification nomenclature NAFLD have long been controversial topic, until 2020 when group international experts recommended substituting MAFLD (metabolic dysfunction-associated FLD). was then terminologically complemented in 2023 by altering it MASLD, i.e., metabolic steatotic (MASLD). Both MASLD terminologies comprise element disorder, as they offer diagnostic benchmarks are embedded risk factors underlie disease. (as multisystemic disease) provides comprehensive definition includes larger population patients who at morbidity mortality, well adverse cardiovascular diabetes outcomes. highlights risks lean or normal weight individuals, factor has not accentuated discussed previous guidelines. Novel antihyperglycemic agents, anti-hyperlipidemic drugs, lifestyle modifications, nutritional interventions, exercise therapies extensively studied MASLD. Nutrition plays vital role managing both conditions, where centralizing on diet rich whole vegetables, fruits, foods, healthy fats, proteins, specific nutrients (e.g., omega-3 acids fibers) can improve insulin resistance reduce inflammation. Thus, essential understand nutrition these conditions work develop an individualized plan for optimal health. This review discusses prevention strategies NAFLD/MAFLD/MASLD management, particular attention correction.

Language: Английский

Citations

18